SOLIRIS® - (Eculizumab) Products
SOLIRIS® is a first-in-class terminal complement inhibitor which works by electively inhibiting activation of specific proteins in the complement system (c5 and c5b), which play a role in the treatment of multiple rare diseases.1
Nufactor carries SOLIRIS (Eculizumab):
Paroxysmal nocturnal hemoglobinuria (PNH),
Atypical hemolytic uremic syndrome (aHUS),
Neuromyelitis optica spectrum disorder (NMOSD)
1 Alexion Pharmaceuticals. Soliris® (Eculizumab). Alexion.com/products/SolirisClick here for a SOLIRIS (Eculizumab) order form.